Open AccessEfficacy and Toxicity of Doxorubicin/Cyclophosphamide Maintenance Therapy in Dogs with Multicentric Lymphosarcoma
Author(s) -
Price G. Sylvester,
Page Rodney L.,
Fischer Bernard M.,
Levine Jay F.,
Gerig Thomas M.
Publication year - 1991
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.1991.tb03131.x
Subject(s) - medicine , hypoalbuminemia , cyclophosphamide , neutropenia , doxorubicin , toxicity , canine lymphoma , gastroenterology , chemotherapy , cardiotoxicity , surgery
Doxorubicin/cyclophosphamide were evaluated as maintenance drugs for dogs with multicentric lymphosarcoma (n = 28). Median remission time of all dogs was 173 days. Remission duration was shorter, however, in dogs with stage IV/V disease, in dogs with pretreatment hypoalbuminemia, and in dogs that had received glucocorticoids before initiation of chemotherapy ( P < 0.04). Nineteen dogs were evaluable for toxicity. Dose‐limiting gastrointestinal toxicosis was observed in three dogs, neutropenia was observed in three dogs, and cardiomyopathy was observed in three dogs. The doxorubicin/cyclophosphamide protocol described in this report is safe and effective in treating canine multicentric lymphosarcoma. Clinical stage, pretreatment steroid therapy, and hypoalbuminemia are prognostic factors for response to this protocol